Search

A clear relationship between intrauterine development and later life predisposition to long-term disease is well established. Weight at birth provides a surrogate measure for fetal development and low birth weight predicts changes in most endocrine axes in adulthood. The exposure of the fetus to elevated levels of either endogenous or synthetic glucocorticoids, pre and periconceptional nutritional status and immediate postnatal development including catch-up growth all contribute substantially to the development of adult onset disease. Fetal exposure to high levels of glucocorticoids has direct clinical relevance. Synthetic glucocorticoids (betamethasone / dexamethasone) are administered to women at risk of preterm delivery to advance fetal maturation and reduce neonatal morbidity and mortality. However, in human pregnancy, evidence suggests that fetal exposure to synthetic glucocorticoids has detrimental effects on birth outcome, childhood cognition and long-term behavior. Studies in animals have established a link between prenatal exposure to synthetic glucocorticoids and alterations in fetal development as well as changes in placental function. These developmental alterations appear to be permanent. Whether this is the case in humans awaits long-term follow-up of children enrolled in randomized controlled trials of prenatal glucocorticoid therapy. The research challenges in this field are now centered on uncovering the mechanisms by which glucocorticoids are involved in programming the fetus for its future life, and discovering ways in which the effectiveness and safety of antenatal glucocorticoids can be enhanced. The purpose of this mini-review is to provide a background into the use of antenatal synthetic corticosteroids and to highlight and summarize recently published clinical and animal-based studies.

Objective To determine effects of maternal or fetal injections of betamethasone on postnatal growth and arterial pressure. Study design We measured body weight, arterial pressure, and heart rate serially in sheep born after single or repeated maternal or fetal betamethasone injections. At approximately 3.5 years, organ weights were measured. Results Repeated maternal betamethasone injections caused intrauterine growth restriction, and low body weight and blood pressure at 3 months. From 6 months to 3 years, body weight, blood pressure, and heart rate were not affected by treatment. At approximately 3.5 years, brain weight was reduced after single or repeated maternal betamethasone by 13% and 18%, respectively ( P =.001). Fetal betamethasone reduced brain weight by 7% to 8% ( P =.018). Weights of other organs were not affected by treatment. Brain weight was unrelated to body weight at approximately 3.5 years ( P =.649) but was related to birth weight ( P =.029). Conclusion Prenatal betamethasone does not have long-term effects on blood pressure but causes a persistent deficit in brain weight.

Many chronic diseases of adulthood, such as hypertension and diabetes, are now believed to have at least some of their origins before birth. Extensive studies in animal models have identified antenatal exposure to excess glucocorticoids as a leading candidate for the physiological cause of fetal compromise. The resulting adverse intra-uterine environment appears to "program" the individual for higher risk of subsequent disease. We present an analysis of blood glucose and insulin concentrations collected during glucose tolerance tests at 6 and 12 months postnatal age in a cohort of sheep that were treated antenatally with injections of betamethasone (a synthetic glucocorticoid) which, when injected into the mother, cross the placenta to the fetus. A simple pharmacokinetic model, essentially a modification of the single compartment model with first-order absorption and elimination, is developed to describe the time course of glucose concentration and the associated insulin response. The resulting nonlinear mixed model is implemented in a Bayesian framework using the Markov chain Monte Carlo technique Gibbs Sampling via the software package BUGS. This sampling process allows inferences to be made directly about derived quantities with an immediate physical interpretation, such as the maximum insulin concentration in response to glucose challenge. At 6 months postnatal age, sheep treated with antenatal injections of synthetic glucocorticoids had raised insulin concentration in comparison to controls after bolus administration of glucose. This effect persisted to 12 months postnatal age only in the sheep that received multiple doses of glucocorticoids. Moreover, the raised insulin concentration in sheep that received direct injections of synthetic glucocorticoid as fetuses is accompanied by better glucose clearance than in those sheep that received only saline injections, a phenomenon that is not observed in the animals that received maternal injections. It is argued that the fitting of an appropriate statistical model to complex physiological data does not necessarily proclude a result that has a clear interpretation for clinical scientists.

There is now overwhelming evidence that much of our predisposition to adult illness is determined by the time of birth. These diseases appear to result from interactions between our genes, our intrauterine environment and our postnatal lifestyle. Those at greatest risk are individuals in communities making a rapid transition from lives of 'thrift' to a lives of 'plenty'. From a global perspective, such origins of diabetes, coronary heart disease and stroke, should render research in these fields as one of the highest priorities in human health care. Prevention will be enhanced by elucidation of the mechanisms by which the fetus is programmed by the mother for the life she expects it to live. At the present time, there is evidence that fetal nutrition and premature exposure to cortisol are effective intrauterine triggers, but a multitude of alternative pathways require investigation. It is also likely that programming extends across generations, and may involve the embryo and perhaps the oocyte. An oocyte that becomes an adult human develops in the uterus of its grandmother, so further research is required to describe the role of environments of grandmothers and mothers in predisposing offspring to health or illness in adult life.

Prenatal glucocorticoid exposure has been associated with a reduction in birth weight and postnatal alterations in glucose homeostasis and hypothalamic-pituitary-adrenal (HPA) axis function. The mechanisms underlying these responses are unknown, although changes in fetal hepatic development may play an important role. The fetal liver produces key regulators of fuel metabolism and of the developing HPA axis that are altered by glucocorticoids. The local availability of glucocorticoids is regulated, in part, by corticosteroid-binding protein (CBG), glucocorticoid receptors (GR) and by the enzyme 11beta-hydroxysteroid dehydrogenase (11betaHSD), but the effects of maternal glucocorticoid administration on the expression of these genes in the fetal liver are unknown. 11betaHSD1 is the predominant form of this enzyme present in the liver and is responsible for the conversion of cortisone to cortisol. To determine if prenatal glucocorticoid exposure alters fetal hepatic regulation of CBG, 11betaHSD1 and GRs, we treated pregnant ewes with betamethasone (0.5 mg/kg) intramuscularly at 104, 111 and 118 days of gestation (term 150 days). Animals were killed at 125 or 146 days of gestation. Maternal betamethasone administration did not alter mean cord plasma glucose but significantly decreased cord plasma insulin levels (P

Prenatal exposure to glucocorticoids is associated with alterations in fetal growth and endocrine function. However, few studies have examined the effects of clinically relevant doses of glucocorticoids on postnatal hypothalamic-pituitary-adrenal (HPA) function. To determine the effects of maternal or fetal betamethasone administration (0.5 mg/kg maternal or estimated fetal weight) on postnatal HPA function at 6 months and 1 year postnatal age, pregnant ewes were randomized into the following treatment groups: no treatment (n=6); maternal saline (n=6); single maternal betamethasone (M1) (n=6); repeated maternal betamethasone (M4) (n=6); fetal saline (n=5); single fetal betamethasone (n=6) and repeated fetal betamethasone (F4) (n=6). Single injections were given at 104 days of gestation and repeated injections at 104, 111, 118 and 125 days. Lambs were born spontaneously and the ACTH and cortisol responses to i.v. corticotropin-releasing hormone (CRH) (0.5 microg/kg) plus arginine vasopressin (AVP) (0.1 microg/kg) were measured at 6 months and 1 year postnatally. At 6 months postnatal age, neither maternal nor fetal prenatal betamethasone administration altered significantly the ACTH and cortisol responses to CRH+AVP. However, in animals at 1 year postnatal age, a previous single injection of betamethasone to the mother (M1) resulted in significantly elevated basal and stimulated cortisol levels (P

The incidence of obesity and overweight has almost doubled in Western societies over the last 2 decades, a trend mirrored in developing nations transitioning to first-world economies. Obesity is strongly associated with the comorbidities of type 2 diabetes, hyperten- sion, and heart disease and represents an enormous burden to health care systems. Of even more concern is the increase of around 40% in the prevalence of childhood obesity and type 2 diabetes over the last 20 years. Metabolic disease results from complex interactions of many factors, including genetic, physiologic, behavioral, and environmental influences. The recent rate at which these diseases have increased suggests that environmental, eg, epigenetic, and behavioral influences, rather than genetic causes, are fuelling the present epidemic. In this context, the developmental origins of health and disease hypothesis has highlighted the link between periconceptual, fetal, and early infant phases of life and the subsequent development of adult obesity and related metabolic disorders. Both maternal undernutrition (global and tar- geted) and maternal obesity elicit an obese offspring phenotype. This review will examine the role of altered maternal nutrition on obesity risk in offspring, the interactions with the postnatal nutritional environment, the possible strategies for intervention, and the role of epigenetics in the disease process.

Pre-term birth remains one of the major unsolved problems in human health. The incidence is increasing in many Western countries, despite several decades of research studies aimed at findings ways that early birth may be prevented. Nearly two-thirds of very early pre-term births are associated with features of inflammation in the newborn, suggesting that infection may be the origin. Many studies have focussed on the possibility that pre-labour rupture of membranes or the early onset of uterine activity may result from infection spreading upward from the vagina. Unfortunately, trials designed to identify potential pathogens in the genital tract followed by appropriate use of antibiotics have failed to prevent prematurity. The strong association between features of intra-uterine inflammation and pre-term birth, and the ineffectiveness of antibiotics to prevent the problem, suggest that the source of inflammation may be from a distant site. We are addressing the possibility that the site may be the gums. Periodontal disease affects 15% of the adult Australian population, is often undiagnosed and is not responsive to systemic antibiotic therapy. In our pregnant population, we have shown that periodontal disease is strongly associated with low birth weight. Our sheep studies have taught us that the lipopolysaccharides (LPS) from periodontal pathogens, when injected into the amniotic cavity, have much greater lethality than enteric LPS, and similar effects in inducing inflammation. We are now investigating the effects of treating periodontal disease during mid-pregnancy in a randomised controlled trial, which aims to screen approximately 5000 pregnant women and allocates those with periodontal disease to treatment during pregnancy or soon after. This study is known as the Smile Study and commenced in February 2005. Improving oral health is an exciting, but yet unproven, strategy by which a major health problem may be prevented by a relatively simple and community-based intervention.

Background Although an adverse early-life environment has been linked to an increased risk of developing the metabolic syndrome, the molecular mechanisms underlying altered disease susceptibility as well as their relevance to humans are largely unknown. Importantly, emerging evidence suggests that these effects operate within the normal range of birth weights and involve mechanisms of developmental palsticity rather than pathology. Method To explore this further, we utilised a non-human primate model Macaca fascicularis (Cynomolgus macaque) which shares with humans the same progressive history of the metabolic syndrome. Using microarray we compared tissues from neonates in the average birth weight (50-75th centile) to those of lower birth weight (5-25th centile) and studied the effect of different growth trajectories within the normal range on gene expression levels in the umbilical cord, neonatal liver and skeletal muscle. Results We identified 1973 genes which were differentially expressed in the three tissue types between average and low birth weight animals (P < 0.05). Gene ontology analysis identified that these genes were involved in metabolic processes including cellular lipid metabolism, cellular biosynthesis, cellular macromolecule synthesis, cellular nitrogen metabolism, cellular carbohydrate metabolism, cellular catabolism, nucleotide and nucleic acid metabolism, regulation of molecular functions, biological adhesion and development. Conclusion These differences in gene expression levels between animals in the upper and lower percentiles of the normal birth weight range may point towards early life metabolic adaptations that in later life result in differences in disease risk.

Our aim was to determine the postnatal effects of single and repeated glucocorticoid injections during late gestation. Repeated (104, 111, 118, 125 days) or single (104 days) injections of betamethasone or saline were given to the ewe or by ultrasound guided injection to the fetus (term 150 days). Lambs were born spontaneously and studied at 3 and 6 mo and 1 yr of age. Arterial pressure was measured at each age, and we performed intravenous glucose tolerance tests at 6 mo and 1 yr. Repeated maternal, but not single maternal or fetal, betamethasone injections prolonged gestation, reduced weight at birth and 3 mo, and was associated with low arterial pressure at 3 mo but not at 6 mo and 1 yr. Glucose metabolism was altered in all betamethasone treatment groups, regardless of the number or route of injections. Our data demonstrate that glucocorticoid-induced fetal growth restriction is associated with a transient reduction in postnatal arterial pressure, but glucocorticoid exposure with or without growth restriction alters glucose metabolism.